UNIVERSITAS
GADJAH MADA
PERBEDAAN NILAI ACTIVATED PARTIAL TROMBOPLASTIN TIME ANTARA KELOMPOK HIPERTENSI DAN NONHIPERTENSI PADA PASIEN DIABETES MELITUS DENGAN TERAPI INJEKSI INTRAVITREAL BEVACIZUMAB
ANIK IKA WINARNI, Dr. Angela Nurini Agni, SpM(K), M.Kes.; Dr. dr. Retno Ekantini, SpM(K), M.Kes
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abdullah, W. Z., Moufak, S. K., Yusof, Z., *et al.* (2010) Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event, *Transl. Res.* Mosby, Inc., 155(6), pp. 315–319.

Adaeze, N. N., Emeribe, A. U., Nasiru, I. A., *et al.* (2014) Evaluation of Prothrombin Time and Activated Partial Thromboplastin Time in Hypertensive Patients Attending a Tertiary Hospital in Calabar , Nigeria, *Hindawi Publ. Corp. Adv. Hematol.*, 2014.

Adams, R. L. C. and Bird, R. J. (2009) Review article : Coagulation cascade and therapeutics update : Relevance to nephrology . Part 1 : Overview of coagulation , thrombophilias and history of anticoagulants, *J. Compil. Asian Pacific Soc. Nephrol.*, 14, pp. 462–470.

Al-Droos, M. and Qubain, W. (2014) The Effect of Intravitreal Avastin on Systemic Blood Pressure in Controlled Hypertensive Patients, *Med. J. Islam. World Acad. Sci.*, 21(2), pp. 77–80.

Alahmari, A. K., Almalki, Z. S., Alahmari, A. K., *et al.* (2016) Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: A meta-analysis of randomized controlled trials, *Am Heal. Drug Benefits*, 9(4), pp. 221–231.

Altinkaynak, H., Ece, M., Piraye, K., *et al.* (2017) Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration, *Int Ophthalmol.* Springer Netherlands.

Alzahrani, S. H. and Ajjan, R. A. (2015) Coagulation and fibrinolysis in diabetes, *Diabetes Vasc. Dis. Res.*, 7(4), pp. 260–273.

Amadio, M., Govoni, S. and Pascale, A. (2016) Targeting VEGF in eye neovascularization : What ' s new ? A comprehensive review on current therapies and oligonucleotide-based interventions under development, *Pharmacol. Res.* Elsevier Ltd, 103, pp. 253–269.

Anderson, J., Hogg, K. and Weitz, J. (2018) *Chapter 140. Hypercoagulable states*. Seventh Ed, *Hematol. Basic Princ. Pract.* Seventh Ed. Elsevier Inc.

Azmeh (2016) Ocular and Systemic Vascular Adverse Events Following Intravitreal Bevacizumab Injection, *J Ophthal Vis Sci*, 1(1).

Blasi, A. (2015) Coagulopathy in liver disease: Lack of an assessment tool, *World J. Gastroenterol.*, 21(35), pp. 10062–10071.

Brook, R. D. and Julius, S. (2000) Autonomic Imbalance, Hypertension, and Cardiovascular Risk, *AJH*, 13, pp. 112–122.

Cardenas, J. C. and Church, F. C. (2016) Overview of Blood Coagulation and Pathophysiology of Blood Coagulation Disordes, *Encycl. Cell Biol.* Elsevier Ltd.

Chan, W. M., Lai, T. Y. Y., Liu, D. T. L., *et al.* (2007) Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin, *Am J Ophthalmol*, 143(6), pp. 977–984.

UNIVERSITAS
GADJAH MADA
PERBEDAAN NILAI ACTIVATED PARTIAL TROMBOPLASTIN TIME ANTARA KELOMPOK HIPERTENSI DAN NONHIPERTENSI PADA PASIEN DIABETES MELITUS DENGAN TERAPI INJEKSI INTRAVITREAL BEVACIZUMAB
ANIK IKA WINARNI, Dr. Angela Nurini Agni, SpM(K), M.Kes.; Dr. dr. Retno Ekantini, SpM(K), M.Kes
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Chee, Y. (2014) Coagulation, *J R Coll Physicians Edinburgh*, pp. 42–45.

Chen, H. X. and Cleck, J. N. (2009) Adverse effects of anticancer agents that target the VEGF pathway, *Nat. Rev. Clin. Oncol.* Nature Publishing Group, 6(8), pp. 465–477.

Christensen, K. L. and Buus, N. H. (2012) Dissociation of blood pressure and resistance artery structure: Potential clinical implications, *Basic Clin. Pharmacol. Toxicol.*, 110(1), pp. 73–79.

Costagliola, C., Agnifili, L., Arcidiacono, B., *et al.* (2012) Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration, *Expert Opin. Biol. Ther*, 12(10), pp. 1299–1313.

Egan, B., Zhao, Y. and Brzezinsky, W. (2012) Epidemiology of Hypertension in Diabetes, in Veves, A. (ed.) *Diabetes Hypertens.* New York: Springer New York Heidelberg Dordrecht London, pp. 1–12.

Falavarjani, K. G. and Nguyen, Q. D. (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents : a review of literature, *Eye Res. Center, Rassoul Akram Hosp. Tehran, Iran*. Nature Publishing Group, 27(7), pp. 787–794.

Foex, P. and Sear, J. (2004) Hypertension : pathophysiology and treatment, *Contin. Educ. Anesth. Crit. Care Pain*, 4(3), pp. 71–75.

Fogli, S., Del Re, M., Rofi, E., *et al.* (2018) Clinical pharmacology of intravitreal anti-VEGF drugs, *Eye*, 32(6), pp. 1010–1020.

Fong, D. S., Custis, P., Howes, J., *et al.* (2010) Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration. A Multicenter, Retrospective Study, *Ophthalmology*. Elsevier Inc., 117(2), pp. 298–302.

Fortin, Mintzes and Innes (2013) CADTH Technology Overviews A Systematic Review of Intravitreal Bevacizumab for Bevacizumab Versus Sham, *Can. Agency Drugs Technol. Heal.*, 3(1), pp. 1–9.

Gao, K., Shi, X. and Wang, W. (2017) The life-course impact of smoking on hypertension, myocardial infarction and respiratory diseases, *Sci. Rep.* Springer US, 7(1), pp. 1–7.

Giles, T. D., Materson, B. J., Cohn, J. N., *et al.* (2009) Definition and Classification of Hypertension : An Update, *J Clin Hypertens*, 11(11), pp. 611–614.

Guan, Q., Fang, L., Zhang, X., *et al.* (2018) Prevalence, awareness, treatment and control of diabetes mellitus among middle-aged and elderly people in a rural Chinese population: A cross-sectional study, *PLoS One*, 13(6), p. e0198343.

Harandi, T. F., Taghinasab, M. M. and Nayeri, T. D. (2017) Deep Vein Thrombosis among Hypertensive Patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia, *Electron. physician*, 9(9), pp. 1–17.

Humar, R., Zimmerli, L. and Battegay, E. (2009) Angiogenesis and hypertension : an update, *J. Hum. Hypertens.* Nature Publishing Group, 23(12), pp. 773–782.

Jiskani, A., Memon, S. and Naseem, L. (2017) Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and International

UNIVERSITAS GADJAH MADA
PERBEDAAN NILAI ACTIVATED PARTIAL TROMBOPLASTIN TIME ANTARA KELOMPOK HIPERTENSI DAN NONHIPERTENSI PADA PASIEN DIABETES MELITUS DENGAN TERAPI INJEKSI INTRAVITREAL BEVACIZUMAB
ANIK IKA WINARNI, Dr. Angela Nurini Agni, SpM(K), M.Kes.; Dr. dr. Retno Ekantini, SpM(K), M.Kes
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Normalized Ratio (INR) as Predictive Factors of Coagulopathy in Newly Diagnosed Hypertensive Patients, *Hematol Transfus Int J*, 4(3).

Klein, A. and Loewenstein, A. (2016) Therapeutic Monoclonal Antibodies and Fragments : Bevacizumab, *Dev. Ophthalmol. Basel. Karger*, 55, pp. 232–245.

Kuk, A., Magnowska, M., Suchy, W., *et al.* (2017) Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab, *Targ Oncol*. Targeted Oncology, 12, pp. 495–503.

Lee, J. W., Park, H., Choi, J. H., *et al.* (2016) Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab, *BMC Ophthalmol.* BMC Ophthalmology, 16(1), pp. 4–10.

Lip, G. (2000) Hypertension and the prothrombotic state, *jhh*, 14, pp. 687–690.

Loutfi, M., Siddiqui, M. R. S., Dhedhi, A., *et al.* (2015) A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation, *SaudiOpthalmolJournal*, 29(2), pp. 147–155.

Lu, Y., Su, L. and Xu, X. (2013) Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis, *J. Ocul. Pharmacol. Ther.*, 29(8), pp. 702–708.

Mao, X., Ait-aissa, K., Lagrange, J., *et al.* (2012) Hypertension , hypercoagulability and the metabolic syndrome : A cluster of risk factors for cardiovascular disease, *Bio-Medical Mater. Enginering*, 22, pp. 35–48.

Mwambungu, A., Kaile, T., Korolova, L., *et al.* (2013) APTT : A Screening Test For Hypercoagulability in Type 2 Diabetes Mellitus Patients, *Med. J. Zambia*, 40(3), pp. 112–120.

Nalluri, S. R., Chu, D. and Keresztes, R. (2008) Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab, *Jama*, 300(19), pp. 2277–85.

Napoleone, F. (2001) Role of Vascular Endothelial Growth Factor in regulation of Physiological Angiogenesis, *Am J Physiol*, (42), pp. 1358–1366.

Napolitano, M., Schmaier, A. H. and Kessler, C. M. (2017) *Chapter 39 - Coagulation and Fibrinolysis*. Twenty Thi, *Henry's Clin. Diagnosis Manag. by Lab. Methods*. Twenty Thi. Elsevier Inc.

Naz, A., Najam, R., Riaz, B., *et al.* (2014) Evaluation of Intravitreal Bevacizumab for Its Systenic Side Effect Thrombosis after Acute Administration, *J App Pharm*, 6(3), pp. 261–267.

Ng, E. W. M. and Adamis, A. P. (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration, *Can J Ophthalmol*. Canadian Ophthalmological Society, 40(3), pp. 352–368.

Pai, M. (2018) *Chapter 129. Laboratory Evaluation of Hemostatic and Thrombotic Disorders*. Seventh Ed, *Hematol. Basic Princ. Pract.* Seventh Ed. Elsevier Inc.

Palta, S., Saroa, R. and Palta, A. (2014) Overview of the coagulation system, *Indian J Anasth*, 58(5), pp. 515–523.

Parikh, R., Ross, J. S., Sangaralingham, L. R., *et al.* (2017) Trends of Anti-

UNIVERSITAS
GADJAH MADA
PERBEDAAN NILAI ACTIVATED PARTIAL TROMBOPLASTIN TIME ANTARA KELOMPOK HIPERTENSI DAN NONHIPERTENSI PADA PASIEN DIABETES MELITUS DENGAN TERAPI INJEKSI INTRAVITREAL BEVACIZUMAB
ANIK IKA WINARNI, Dr. Angela Nurini Agni, SpM(K), M.Kes.; Dr. dr. Retno Ekantini, SpM(K), M.Kes
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients, *Ophthalmology*. Elsevier Inc., 124(3), pp. 352–358.

Platania, C. B. M., Paola, L. Di, Leggio, G. M., *et al.* (2015) Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: A computational approach, *Front. Pharmacol.*, 6(OCT), pp. 1–13.

Poku, E., Rathbone, J., Wong, R., *et al.* (2014) The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: Systematic review, *BMJ*, 4(7).

Pożarowska, D. and Pożarowski, P. (2016) The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology , VEGF and anti-VEGF therapy, *Cent Eur J Immunol*, 41(3), pp. 311–316.

Qian, J. and Jiang, Y. (2011) Decreased prothrombin time after intravitreal bevacizumab in the early period in patients with proliferative diabetic retinopathy, *Acta Ophthalmol*, 89, pp. 332–335.

Ramsey, D. J., Haddock, L. J., Young, L. H., *et al.* (2014) Complications of subspecialty ophthalmic care: Systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway, *Semin. Ophthalmol.*, 29(5–6), pp. 263–275.

Ranpura, V., Hapani, S., Chuang, J., *et al.* (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials, *Acta Oncol. (Madr).*, 49(3), pp. 287–297.

Rasier, R., Artunay, O., Yuzbasioglu, E., *et al.* (2009) The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension, *Eye*. Nature Publishing Group, 23(8), pp. 1714–1718.

Remková, A. and Remko, M. (2010) The role of renin-angiotensin system in prothrombotic state in essential hypertension, *Physiol Res*, 59(1), pp. 13–23.

Rogers, H. J., Nakashima, M. O. and Kottke-Marchant, K. (2018) *Chapter 2. Hemostasis and Thrombosis*. Third Edit, *Hematopathology*. Third Edit. Elsevier Inc.

Semeraro, F., Arcidiano, B. and Costagliola, C. (2011) Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration, *Curr. Vasc. Pharmacol.*, 9(5), pp. 629–646.

Semeraro, F., Morescalchi, F., Duse, S., *et al.* (2015) Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection, *Curr. Drug Metab.*, 16.

Shi, F., Yu, A. and Yuan, L. (2019) Clinical Significance of Detection of Coagulation Indexes , Immune Factors and Inflammatory Factors in Patients with Pregnancy-Induced Hypertension Syndrome in China, *Iran J Public Heal.*, 48(4), pp. 681–687.

De Simone, G., Devereux, R. B., Chinali, M., *et al.* (2005) Association of blood pressure with blood viscosity in American Indians: The Strong Heart Study, *Hypertension*, 45(4), pp. 625–630.

Sira, J. and Eyre, L. (2016) Physiology of haemostasis, *Anaesth. Intensive Care*

UNIVERSITAS
GADJAH MADA
**PERBEDAAN NILAI ACTIVATED PARTIAL TROMBOPLASTIN TIME ANTARA KELOMPOK HIPERTENSI DAN NONHIPERTENSI
PADA PASIEN DIABETES MELITUS DENGAN TERAPI INJEKSI INTRAVITREAL BEVACIZUMAB**
ANIK IKA WINARNI, Dr. Angela Nurini Agni, SpM(K), M.Kes.; Dr. dr. Retno Ekantini, SpM(K), M.Kes
Universitas Gadjah Mada, 2019 | Diunduh dari http://etd.repository.ugm.ac.id/

Med. Elsevier Ltd, pp. 1–4.

Song, J., Drobatz, K. J. and Silverstein, D. C. (2016) Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs : 25 cases (2006 – 2011), *J. Vet. Emerg. Crit. Care*, 26(3), pp. 398–405.

Stewart, M. W. (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology, *Mayo Clin Proc*. Elsevier Inc., 87(1), pp. 77–88.

Subramanian, M., Ness, S., Abedi, G., *et al.* (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: Early results of a prospective double-masked, randomized clinical trial, *Am J Ophthalmol*. Elsevier Inc., 150(2), p. 287.

Triantafyllou, A., Anyfanti, P., Pyrpasopoulou, A., *et al.* (2015) Capillary Rarefaction as an Index for the Microvascular Assessment of Hypertensive Patients, *Curr Hypertens Rep, Springer*.

Wang, E. and Chen, Y. (2003) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis., *Retina*, 33(7), pp. 1375–92.

Yi, Z., Chen, C., Su, Y., *et al.* (2014) Changes in Clotting Time , Plasma Fibrinogen Levels , and Blood Viscosity After Administration of Ranibizumab for Treatment of Choroidal Neovascularization, *Curr. Eye Res.*, (238), pp. 1–6.

Yilmaz, T. and Cordero-Coma, M. (2012) Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: A systematic review, *Graefes Arch Clin Ophthalmol*, 250(6), pp. 787–793.